330 related articles for article (PubMed ID: 14969649)
1. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial.
Dailey GE; Noor MA; Park JS; Bruce S; Fiedorek FT
Am J Med; 2004 Feb; 116(4):223-9. PubMed ID: 14969649
[TBL] [Abstract][Full Text] [Related]
2. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Garber A; Klein E; Bruce S; Sankoh S; Mohideen P
Diabetes Obes Metab; 2006 Mar; 8(2):156-63. PubMed ID: 16448519
[TBL] [Abstract][Full Text] [Related]
3. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study.
Garber AJ; Bruce S; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1401-13. PubMed ID: 12380632
[TBL] [Abstract][Full Text] [Related]
4. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
Kahn SE; Haffner SM; Heise MA; Herman WH; Holman RR; Jones NP; Kravitz BG; Lachin JM; O'Neill MC; Zinman B; Viberti G;
N Engl J Med; 2006 Dec; 355(23):2427-43. PubMed ID: 17145742
[TBL] [Abstract][Full Text] [Related]
5. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
Davidson JA; McMorn SO; Waterhouse BR; Cobitz AR
Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
[TBL] [Abstract][Full Text] [Related]
6. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
Dailey GE; Mohideen P; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
Dobs AS; Goldstein BJ; Aschner P; Horton ES; Umpierrez GE; Duran L; Hill JS; Chen Y; Golm GT; Langdon RB; Williams-Herman DE; Kaufman KD; Amatruda JM; Ferreira JC
J Diabetes; 2013 Mar; 5(1):68-79. PubMed ID: 22742523
[TBL] [Abstract][Full Text] [Related]
8. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Fonseca V; Rosenstock J; Patwardhan R; Salzman A
JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
[TBL] [Abstract][Full Text] [Related]
9. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.
Bailey CJ; Bagdonas A; Rubes J; McMorn SO; Donaldson J; Biswas N; Stewart MW
Clin Ther; 2005 Oct; 27(10):1548-61. PubMed ID: 16330291
[TBL] [Abstract][Full Text] [Related]
11. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes.
Karyekar C; Donovan M; Allen E; Fleming D; Ravichandran S; Chen R
Postgrad Med; 2011 Jul; 123(4):63-70. PubMed ID: 21680990
[TBL] [Abstract][Full Text] [Related]
13. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.
Lewin A; Lipetz R; Wu J; Schwartz S
Clin Ther; 2007 May; 29(5):844-855. PubMed ID: 17697903
[TBL] [Abstract][Full Text] [Related]
14. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
Raz I; Stranks S; Filipczak R; Joshi P; Lertoft B; Rastam J; Chow CC; Shaban J
Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416
[TBL] [Abstract][Full Text] [Related]
16. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
[TBL] [Abstract][Full Text] [Related]
17. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.
Panikar V; Chandalia HB; Joshi SR; Fafadia A; Santvana C
J Assoc Physicians India; 2003 Nov; 51():1061-4. PubMed ID: 15260389
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
20. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI
Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]